Calico Life Sciences, an Alphabet subsidiary focused on aging research, entered an exclusive licensing agreement with Mabwell Bioscience for rights to the anti-IL-11 monoclonal antibody, 9MW3811, outside Greater China135.
Calico will make a $25 million upfront payment and up to $571 million in development, regulatory, and commercial milestone payments, totaling up to $596 million13.
9MW3811 targets the IL-11 cytokine to suppress inflammatory responses, and its potential application is in aging and age-related diseases13.
The antibody is already in Phase I trials for idiopathic pulmonary fibrosis with approvals to begin clinical trials in China, the U.S., and Australia13.
Mabwell will retain rights within Greater China, while Calico receives exclusive development, manufacturing, and commercialization rights elsewhere135.
Sources:
1. https://www.biospace.com/business/alphabet-subsidiary-calico-colors-in-up-to-570m-aging-deal-with-chinas-mabwell